These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 36011621)

  • 1. Cost-Effectiveness Analysis of the Helicobacter Pylori Screening Programme in an Asymptomatic Population in China.
    Feng T; Zheng Z; Xu J; Cao P; Gao S; Yu X
    Int J Environ Res Public Health; 2022 Aug; 19(16):. PubMed ID: 36011621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of
    Kowada A
    Scand J Gastroenterol; 2019 Jun; 54(6):685-689. PubMed ID: 31190581
    [No Abstract]   [Full Text] [Related]  

  • 3. Endoscopy Is Cost-Effective for Gastric Cancer Screening After Successful Helicobacter pylori Eradication.
    Kowada A
    Dig Dis Sci; 2021 Dec; 66(12):4220-4226. PubMed ID: 33417196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness analysis of population-based serology screening and (13)C-Urea breath test for Helicobacter pylori to prevent gastric cancer: a markov model.
    Xie F; Luo N; Lee HP
    World J Gastroenterol; 2008 May; 14(19):3021-7. PubMed ID: 18494053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Population-Based Helicobacter pylori Eradication Strategy Is More Cost-Effective than Endoscopic Screening.
    Kowada A
    Dig Dis Sci; 2023 May; 68(5):1735-1746. PubMed ID: 36565366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Family-based Helicobacter pylori infection control and management strategy and screen-and-treat strategy are highly cost-effective in preventing multiple upper gastrointestinal diseases in Chinese population at national level.
    Zhang C; Qi YB; Hu RB; Xu L; Li XT; Ma J; Shao QQ; Abdun MA; Ur Rahman I; Shi WJ; Li FQ; Yu JJ; Yuan MK; Chen Q; Lu H; Ding SZ
    Helicobacter; 2024; 29(3):e13063. PubMed ID: 38874128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness of Population-Based Helicobacter pylori Screening With Eradication for Optimal Age of Implementation.
    Kowada A
    Helicobacter; 2024; 29(4):e13120. PubMed ID: 39138610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness Analysis of Helicobacter pylori Eradication Therapy for Prevention of Gastric Cancer: A Markov Model.
    Han Y; Yan T; Ma H; Yao X; Lu C; Li Y; Li L
    Dig Dis Sci; 2020 Jun; 65(6):1679-1688. PubMed ID: 31673902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of screen-and-treat strategy in asymptomatic Chinese for preventing Helicobacter pylori-associated diseases.
    Chen Q; Liang X; Long X; Yu L; Liu W; Lu H
    Helicobacter; 2019 Apr; 24(2):e12563. PubMed ID: 30672082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of different screening strategies for helicobacter pylori infection in Iran: A model-based evaluation.
    Yousefi M; Rezaei S; Khoshbaten M; Sarmasti M
    Helicobacter; 2023 Dec; 28(6):e13027. PubMed ID: 37839058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cost effectiveness of Helicobacter pylori population screening-economic evaluation alongside a randomised controlled trial with 13-year follow-up.
    Høgh MB; Kronborg C; Hansen JM; Schaffalitzky de Muckadell OB
    Aliment Pharmacol Ther; 2019 Apr; 49(8):1013-1025. PubMed ID: 30854700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of Helicobacter pylori screening followed by eradication treatment for employees in Japan.
    Kowada A
    Epidemiol Infect; 2018 Oct; 146(14):1834-1840. PubMed ID: 30056808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Both family-based Helicobacter pylori infection control and management strategy and screen-and-treat strategy are cost-effective for gastric cancer prevention.
    Ma J; Yu M; Shao QQ; Yu XC; Zhang C; Zhao JB; Yuan L; Qi YB; Hu RB; Wei PR; Xiao W; Chen Q; Jia BL; Chen CL; Lu H; Ding SZ
    Helicobacter; 2022 Aug; 27(4):e12911. PubMed ID: 35706404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of Helicobacter pylori screening in prevention of gastric cancer in Chinese.
    Xie F; Luo N; Blackhouse G; Goeree R; Lee HP
    Int J Technol Assess Health Care; 2008; 24(1):87-95. PubMed ID: 18218173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastric adenocarcinoma screening and prevention in the era of new biomarker and endoscopic technologies: a cost-effectiveness analysis.
    Yeh JM; Hur C; Ward Z; Schrag D; Goldie SJ
    Gut; 2016 Apr; 65(4):563-74. PubMed ID: 25779597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Economic Evaluation of Family-Based Versus Traditional Helicobacter pylori Screen-and-Treat Strategy: Based on Real-World Data and Microsimulation Model.
    Ma Y; Zhou X; Liu Y; Xu S; Ma A; Du Y; Li H
    Helicobacter; 2024; 29(4):e13123. PubMed ID: 39108224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A screening program to test and treat for Helicobacter pylori infection: Cost-utility analysis by age, sex and ethnicity.
    Teng AM; Kvizhinadze G; Nair N; McLeod M; Wilson N; Blakely T
    BMC Infect Dis; 2017 Feb; 17(1):156. PubMed ID: 28219322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic and health impacts of introducing Helicobacter pylori eradication strategy into national gastric cancer policy in Japan: A cost-effectiveness analysis.
    Kowada A; Asaka M
    Helicobacter; 2021 Oct; 26(5):e12837. PubMed ID: 34278663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness of Screening Helicobacter pylori for Gastric Cancer Prevention: a Systematic Review.
    Sarmasti M; Khoshbaten M; Khalili F; Yousefi M
    J Gastrointest Cancer; 2022 Dec; 53(4):1093-1103. PubMed ID: 34694594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cost-effectiveness of population Helicobacter pylori screening and treatment: a Markov model using economic data from a randomized controlled trial.
    Mason J; Axon AT; Forman D; Duffett S; Drummond M; Crocombe W; Feltbower R; Mason S; Brown J; Moayyedi P;
    Aliment Pharmacol Ther; 2002 Mar; 16(3):559-68. PubMed ID: 11876711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.